

Accepted Manuscript

In Response: The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids - an alternative perspective

Sukhbir S. Singh, Liane Belland, Nicholas Leyland, Sarah von Riedemann, Ally Murji



PII: S0002-9378(18)30245-X

DOI: [10.1016/j.ajog.2018.03.030](https://doi.org/10.1016/j.ajog.2018.03.030)

Reference: YMOB 12120

To appear in: *American Journal of Obstetrics and Gynecology*

Received Date: 28 February 2018

Accepted Date: 24 March 2018

Please cite this article as: Singh SS, Belland L, Leyland N, von Riedemann S, Murji A, In Response: The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids - an alternative perspective, *American Journal of Obstetrics and Gynecology* (2018), doi: 10.1016/j.ajog.2018.03.030.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Singh et al. Response to Letter to Editor

Reference Manuscript #: L18-015AR1

Title

In Response: The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids - an alternative perspective

Authors:

Sukhbir S. Singh
Liane Belland
Nicholas Leyland
Sarah von Riedemann
Ally Murji

Author Disclosure:

SSS has research grants with Abbvie, Bayer, and Allergan. He has been a consultant and speaker for Abbvie, Bayer and Allergan.

LB has been part of National Advisory Boards for Allergan and Abbvie. She has been part of speakers' bureaus for Allergan, Abbvie, and Bayer.

NL has received research grant support from Allergan, Bayer and Abbvie.

SvR is a full-time employee of SCRIPT, a third-party medical communications agency. SCRIPT received funding from Allergan Canada (as below) for the preparation of the original manuscript.

AM has been part of the speakers' bureau and advisory board for Abbvie, Allergan, Bayer, and Hologic.

Financial support: This letter to the editor had no financial support in its preparation. For the original article, Allergan Canada provided financial support for editorial assistance by the medical writer (SvR). The sponsor did not have any input into the collection, analysis and interpretation of data, or into the clinical recommendations and other content of this article.

Download English Version:

<https://daneshyari.com/en/article/8752402>

Download Persian Version:

<https://daneshyari.com/article/8752402>

[Daneshyari.com](https://daneshyari.com)